CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Health, a biotechnology company pioneering a new approach to address metabolic dysregulation and health, today announced that Manu Chakravarthy, M.D., Ph.D., Senior Vice President, Clinical Development and Chief Medical Officer, will be presenting new data on the company’s novel candidate AXA1125 at the 2018 American Association for the Study of Liver Diseases (AASLD) Meeting, occurring November 9-13, 2018 in San Francisco, CA.
Effective therapies for NAFLD require coordinated reprogramming of cellular physiology as multiple pathways drive liver injury and disease progression. The presentation and poster will show AXA1125, the company’s unique metabolic modulator composition, as a potential candidate to address the multifactorial dysregulation in NAFLD with the goal of safely reprogramming cellular metabolism to simultaneously target insulin resistance, inflammation, and fibrogenesis.
Additional details of the presentation are as follows:
Title: AXA1125, a Novel Composition of Amino Acids Reprograms the Multifactorial Pathophysiology in NAFLD
Presenter: Manu Chakravarthy, M.D., Ph.D., Senior Vice President, Clinical Development and Chief Medical Officer
Session: Parallel 13: Novel Therapeutics for NASH
Location: Moscone Center, North and South Buildings, Room 24/25
Date/Time: Sunday, November 11 at 2:45 PM
About Axcella™ Health
Metabolic dysregulation is at the heart of many diseases and maintaining metabolic function is core to health. Axcella is designing and developing endogenous metabolic modulator compositions with the goal of addressing metabolic dysregulation by safely reprogramming metabolism to either treat complex diseases or maintain health. With our diverse and expanding platform, we are transforming traditional discovery and development of drugs and health products. Our platform has already produced a rich pipeline of product candidates in programs that include liver, muscle, and CNS. Axcella Health was founded by Flagship Pioneering. www.axcellahealth.com